# OnCo record low-risk-gtn (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/low-risk-gtn/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "low-risk-gtn" ;
  schema:name "Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6)"@en ;
  schema:alternateName "Low-risk GTN"@en, "Post-molar gestational trophoblastic neoplasia"@en, "Persistent trophoblastic disease"@en, "Invasive mole and low-risk choriocarcinoma"@en ;
  schema:description "Low-risk gestational trophoblastic neoplasia is the mild form of this rare pregnancy-related cancer, usually found when the pregnancy hormone hCG fails to fall after removal of a molar pregnancy. It is cured in almost every woman with a single chemotherapy drug, methotrexate or actinomycin D, given until the hormone level is normal, and most go on to have normal pregnancies afterwards."@en ;
  schema:url <https://onco.cc/cancers/low-risk-gtn/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Gestational_trophoblastic_disease> ;
  schema:citation <https://doi.org/10.1200/JCO.2010.30.4386>, <https://doi.org/10.1200/JCO.20.00803>, <https://en.wikipedia.org/wiki/Gestational_trophoblastic_disease> ;
  onco:tag "subtype-page", "gynaecologic" ;
  onco:related <https://onco.cc/cancers/high-risk-gtn/>, <https://onco.cc/cancers/placental-site-trophoblastic-tumour/>, <https://onco.cc/cancers/gestational-trophoblastic/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/ultrasound/>, <https://onco.cc/technologies/fertility-preservation/>, <https://onco.cc/technologies/serum-tumour-markers/> ;
  onco:targets <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/dactinomycin/>, <https://onco.cc/drugs/avelumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/vincristine/> ;
  onco:terms <https://onco.cc/terms/tumour-markers/>, <https://onco.cc/terms/staging-systems/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-gog-174-methotrexate-vs-dactinomycin-low-risk-gtn-jco-2011/>, <https://onco.cc/key-papers/paper-trophimmun-avelumab-chemoresistant-gtn-jco-2020/>, <https://onco.cc/key-papers/paper-figo-2000-staging-gestational-trophoblastic-neoplasia-ijgo-2002/> ;
  onco:pipeline <https://onco.cc/drugs/avelumab/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:standardOfCare <https://onco.cc/technologies/ultrasound/>, <https://onco.cc/terms/tumour-markers/>, <https://onco.cc/terms/staging-systems/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/dactinomycin/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/drugs/dactinomycin/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/avelumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/technologies/fertility-preservation/>, <https://onco.cc/terms/tumour-markers/> .